Life Science – Regulation Gives Way To Innovation
Over the decade of the 2000s it became increasingly clear that structural issues made investing in biotech companies a high-risk, low return game. The clinical trial process lasted a decade, and cost...
6 years in venture, dozens of convos w LPs, 4 key questions to each & ~12K words that aim to demystify the opaque ... 🌏 of #LP investing.
To be or not to be an LP
What makes a phenomenal (vs good) GP
Common advice to ignore
Bravo @cupazhou 👏👏👏
📣 Be sure you are subscribed to the monthly #OpenLP newsletter! September issue dropping in inboxes tomorrow 📨
🔔Deadline extended! Be sure to participate in the #VCHumanCapital survey & sign the pledge by 9/30!
👏Thank ... you @nvca, @VCForward & @DeloitteUS for leading this charge to help advance #diversity #equity & #inclusion efforts in the 🇺🇸 #VC industry.
There’s a lot of talk about when to buy, but rarely when to sell. With no hard & fast best practices for secondary... transactions, @hunterwalk & the team at @Homebrew codified their own. Their thoughts on turning unrealized gains into partially realized 👇